Crystal's MCW Coder Hub🧬ICD-10 CM C67.9 - Malignant neoplasm of bladder, unspecified
Code Classification
Clinical Description
C67.9 represents a primary or metastatic malignant neoplasm involving the bladder when the specific subsite or histologic type is not documented. The bladder is a hollow organ in the lower abdomen that stores urine; bladder cancer occurs in the lining of the bladder and is the sixth most common type of cancer in the United States.
Common Clinical Presentations
- Hematuria (blood in urine)
- Frequent urge to urinate
- Dysuria (painful urination)
- Low back pain
- Urinary frequency or urgency without infection
Risk Factors
- Tobacco smoking (strongest risk factor)
- Occupational exposure to aromatic amines (dye, rubber, leather, paint industries)
- Chronic bladder inflammation or infection
- Family history of bladder cancer
- Age >55, male sex, White race
Code Hierarchy / Tree
C00-D49 Neoplasms
└─ C64-C68 Malignant neoplasms of urinary tract
└─ C67 Malignant neoplasm of bladder
├─ C67.0 Malignant neoplasm of trigone of bladder
├─ C67.1 Malignant neoplasm of dome of bladder
├─ C67.2 Malignant neoplasm of lateral wall of bladder
├─ C67.3 Malignant neoplasm of anterior wall of bladder
├─ C67.4 Malignant neoplasm of posterior wall of bladder
├─ C67.5 Malignant neoplasm of bladder neck
├─ C67.6 Malignant neoplasm of ureteric orifice
├─ C67.7 Malignant neoplasm of urachus
├─ C67.8 Malignant neoplasm of overlapping sites of bladder
└─ [[C67.9]] Malignant neoplasm of bladder, unspecified ← THIS CODE
Coding Best Practice
Includes / Excludes Notes
Includes (Applicable To)
- Bladder cancer NOS
- Carcinoma of urinary bladder, unspecified site
- Primary malignant neoplasm of bladder, site not specified
- Transitional cell carcinoma of bladder, unspecified location
Excludes1 (Never code together - mutually exclusive)
| Code | Description | Rationale |
|---|---|---|
| D09.0 | Carcinoma in situ of bladder | In situ vs. invasive malignancy |
| D30.3 | Benign neoplasm of bladder | Benign vs. malignant behavior |
| D41.4 | Neoplasm of uncertain behavior of bladder | Uncertain vs. confirmed malignant |
| Z85.51 | Personal history of malignant neoplasm of bladder | History vs. active disease |
Excludes2 (May code together if both conditions exist)
| Code | Description | When to Use Both |
|---|---|---|
| C79.00 | Secondary malignant neoplasm of kidney and renal pelvis | If bladder cancer has metastasized |
| C79.11 | Secondary malignant neoplasm of bladder | If primary is elsewhere with bladder mets |
| N32.81 | Overactive bladder | If symptomatic bladder dysfunction coexists |
| N30.00 | Acute cystitis | If concurrent infection present |
Chapter-Level Notes (C00-D49)
- Functional Activity: All neoplasms are classified in Chapter 2 regardless of functional activity. Use additional code from Chapter 4 to identify hormone secretion or other functional activity if applicable.
- Morphology/Histology: Chapter 2 classifies by site (topography). Use Table of Neoplasms for correct topography. Morphology codes (M-codes) may be added for tumor histology when documented.
- Overlapping Sites: Primary malignant neoplasm involving two or more contiguous bladder subsites should be coded to C67.8 (overlapping lesion), not C67.9.
- Multifocal Tumors: Assign C67.9 when tumor is multifocal (separate tumors in more than one subsite) and specific subsite of origin cannot be determined.
HCC Risk Adjustment Status
CMS-HCC Model V24 (2023-2025 Transition)
| Attribute | Value |
|---|---|
| HCC Category | HCC 11 - Colorectal, Bladder, and Other Cancers |
| Relative Factor (RAF) | 0.307 |
| Model Status | Phased out; blended with V28 during transition years |
CMS-HCC Model V28 (Full Implementation 2026)
| Attribute | Value |
|---|---|
| HCC Category | HCC 22 - Colorectal, Bladder, and Other Cancers |
| Relative Factor (RAF) | 0.363 |
| Model Status | Active; fully implemented for CY 2026 risk adjustment |
HCC Documentation Requirements
- C67.9 must be documented as an active, assessed condition during the encounter to count toward RAF score
- Apply MEAT criteria: Condition must be Monitored, Evaluated, Assessed/Addressed, or Treated during the visit
- Annual recapture required for chronic conditions in Medicare Advantage risk adjustment
- Avoid unspecified codes when more specific documentation is available; query provider if subsite is implied but not stated
MS-DRG Assignment (Inpatient Facility Billing)
C67.9 may group to the following MS-DRGs (v43.0) depending on procedures performed and presence of CC/MCC:
| MS-DRG | Description | Typical Procedures | CC/MCC Impact |
|---|---|---|---|
| 656 | Kidney and ureter procedures for neoplasm with MCC | Cystectomy, ureteral resection | Major Complication/Comorbidity present |
| 657 | Kidney and ureter procedures for neoplasm with CC | Same as above | Complication/Comorbidity present |
| 658 | Kidney and ureter procedures for neoplasm without CC/MCC | Same as above | No CC/MCC |
| 686 | Kidney and urinary tract neoplasms with MCC | Medical management, chemo, radiation | MCC present (e.g., sepsis, respiratory failure) |
| 687 | Kidney and urinary tract neoplasms with CC | Same as above | CC present (e.g., anemia, electrolyte disorder) |
| 688 | Kidney and urinary tract neoplasms without CC/MCC | Same as above | No CC/MCC |
DRG Logic
wRVU and Assistant Payable Status
Diagnosis Code Limitation
C67.9 is an ICD-10-CM diagnosis code, NOT a CPT procedure code. Therefore:
- wRVU (work Relative Value Unit): Not applicable. wRVUs are assigned to CPT/HCPCS procedure codes (e.g., 52224, 51570), not diagnosis codes.
- Assistant Payable: Not applicable. Assistant-at-surgery indicators apply to CPT surgical procedure codes, not diagnosis codes.
To find wRVU/assistant payable data, reference the CPT procedure codes used to treat the condition (e.g., cystoscopy, TURBT, cystectomy).
Coding Examples
Example 1: Initial Diagnosis, Unspecified Subsite
Clinical Scenario: 68M presents with gross hematuria. Cystoscopy reveals malignant-appearing lesion; biopsy pending. Provider documents “bladder cancer” without specifying location.
| Code | Description | Rationale |
|---|---|---|
| C67.9 | Malignant neoplasm of bladder, unspecified | Active malignancy documented; subsite not yet identified |
| R31.0 | Gross hematuria | Symptom prompting evaluation |
TIP
Once pathology returns and subsite is identified (e.g., trigone), update to C67.0 on subsequent encounters.
Example 2: Multifocal Bladder Tumors
Clinical Scenario: Patient undergoes TURBT; pathology shows urothelial carcinoma in both anterior and posterior bladder walls. Provider cannot determine primary site.
| Code | Description | Rationale |
|---|---|---|
| C67.9 | Malignant neoplasm of bladder, unspecified | Multifocal tumors with indeterminate origin per SEER guidelines |
| Z79.899 | Other long term (current) drug therapy | If on maintenance BCG or immunotherapy |
Example 3: Metastatic Disease
Clinical Scenario: Known bladder cancer with new liver metastasis. Primary bladder subsite never documented.
| Code | Description | Rationale |
|---|---|---|
| C67.9 | Malignant neoplasm of bladder, unspecified | Primary site documented as bladder, subsite unspecified |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct | Metastatic site |
| Z85.51 | Personal history of malignant neoplasm of bladder | Do NOT use if cancer is still active; use only after treatment completion with no evidence of disease |
Example 4: Surveillance After Treatment
Clinical Scenario: Patient status post TURBT for bladder cancer 1 year ago; NED (no evidence of disease); presents for routine cystoscopy surveillance.
| Code | Description | Rationale |
|---|---|---|
| Z85.51 | Personal history of malignant neoplasm of bladder | Active cancer resolved; surveillance for recurrence |
| Z12.6 | Encounter for screening for malignant neoplasm of bladder | Screening/surveillance intent |
| Avoid C67.9 | Do not report active cancer code if disease is in remission/NED |
Clinical Documentation Improvement (CDI) Tips
Query Triggers for Specificity
- Documentation states "bladder mass" or "bladder lesion" without behavior → Query: "Is this malignant, benign, or uncertain behavior?"
- Documentation states "bladder cancer" without subsite → Query: "Can the specific bladder subsite be identified (trigone, dome, lateral wall, etc.)?"
- Pathology reports "urothelial carcinoma" but operative note lacks location → Query provider to correlate pathology with cystoscopy findings
- Multifocal tumors documented → Confirm if origin site can be determined; if not, C67.9 is appropriate per coding guidelines
MEAT Criteria Checklist for HCC Capture
For C67.9 to count toward RAF score, documentation should reflect at least one:
- Monitor: “Will monitor bladder cancer progression with serial cystoscopy”
- Evaluate: “Evaluated hematuria in context of known bladder malignancy”
- Assess/Address: “Discussed treatment options for bladder cancer; patient elected intravesical therapy”
- Treat: “Administered BCG instillation for treatment of bladder cancer”
Related Codes
More Specific Bladder Malignancy Codes
- C67.0 - Malignant neoplasm of trigone of bladder
- C67.1 - Malignant neoplasm of dome of bladder
- C67.2 - Malignant neoplasm of lateral wall of bladder
- C67.3 - Malignant neoplasm of anterior wall of bladder
- C67.4 - Malignant neoplasm of posterior wall of bladder
- C67.5 - Malignant neoplasm of bladder neck
- C67.6 - Malignant neoplasm of ureteric orifice
- C67.7 - Malignant neoplasm of urachus
- C67.8 - Malignant neoplasm of overlapping sites of bladder
Non-Malignant Bladder Neoplasm Codes
- D09.0 - Carcinoma in situ of bladder
- D30.3 - Benign neoplasm of bladder
- D41.4 - Neoplasm of uncertain behavior of bladder
History / Screening Codes
- Z85.51 - Personal history of malignant neoplasm of bladder
- Z12.6 - Encounter for screening for malignant neoplasm of bladder
- Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm
Common Procedure Codes (CPT) for Bladder Cancer
- 52224 - Cystourethroscopy with fulguration/treatment of small bladder tumor (<2.0 cm)
- 52234 - Cystourethroscopy with fulguration/treatment of medium bladder tumor (2.0-5.0 cm)
- 52240 - Cystourethroscopy with fulguration/treatment of large bladder tumor (>5.0 cm)
- 51570 - Cystectomy, partial; simple
- 51575 - Cystectomy, partial; complicated
- 51580 - Cystectomy, radical, for bladder cancer
Coding Edits & Compliance Alerts
Common Denial Risks
- Unspecified code overuse: Payers may deny or downcode C67.9 if medical record supports a more specific subsite. Always query when location is implied.
- Active vs. history confusion: Do not report C67.9 for surveillance encounters when cancer is in remission; use Z85.51 instead.
- HCC validation: For RAF capture, ensure C67.9 is linked to clinical assessment/treatment in the same encounter note. Standalone problem list entries may not validate.
- Pathology correlation: If pathology confirms malignancy but operative report lacks location, C67.9 is acceptable; however, best practice is to obtain subsite documentation.
Quick Reference Summary
| Attribute | Value |
|---|---|
| Code | C67.9 |
| Description | Malignant neoplasm of bladder, unspecified |
| Billable | Yes |
| Effective | FY 2026 (10/1/2025) |
| HCC V24 | HCC 11, RAF 0.307 |
| HCC V28 | HCC 22, RAF 0.363 |
| MS-DRGs | 656, 657, 658, 686, 687, 688 |
| wRVU | N/A (diagnosis code) |
| Assistant Payable | N/A (diagnosis code) |
| Excludes1 | D09.0, D30.3, D41.4, Z85.51 |
| Use When | Bladder malignancy documented but subsite not specified or multifocal with indeterminate origin |
Revision History
- 2026-03-12: Initial note creation; updated for FY 2026 ICD-10-CM, HCC V28 full implementation, MS-DRG v43.0
- 2025-10-01: C67.9 remained unchanged from prior year; no code revisions
Key Takeaway
C67.9 is appropriate when bladder cancer is confirmed but the specific subsite cannot be determined after reasonable clinical effort. Prioritize specificity when documentation allows, and ensure active disease is clearly distinguished from history of disease for accurate coding, billing, and risk adjustment.